Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007149316 - HIGH PERFORMANCE RETICULATED ELASTOMERIC MATRIX

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

What is claimed is:

1. An implantable device comprising a reticulated resiliently-compressible elastomeric matrix comprising a plurality of pores, wherein the implantable device further comprises a reinforcement in at least one dimension.

2. The implantable device of claim 1, wherein the reinforcement is a
1 -dimensional reinforcement.

3. The implantable device of claim 2, wherein the 1 -dimensional
reinforcement comprises a plurality of substantially parallel 1 -dimensional reinforcement elements.

4. The implantable device of claim 2, wherein the 1 -dimensional
reinforcement has a substantially circular cross-section with a diameter of from about 0.03 mm to about 1.0 mm, optionally from about 0.07 mm to about 0.30 mm.

5. The implantable device of claim 2, wherein the 1 -dimensional
reinforcement has a substantially circular cross-section equivalent to a USP suture diameter from about size 8-0 to about size 0, optionally from about size 8-0 to about size

2.

6. The implantable device of claim 2, wherein the 1 -dimensional
reinforcement comprises a fiber, a wire, a suture, a yarn, or any mixture thereof.

7. The implantable device of claim 6, wherein the 1 -dimensional
reinforcement comprises mono-filament fiber, multi-filament yarn, braided multifilament yarns, commingled mono-filament fibers, commingled multi-filament yarns, bundled mono-filament fibers, bundled multi-filament yarns, or any mixture thereof.

8. The implantable device of claim 6, wherein the 1 -dimensional
reinforcement comprises an amorphous polymer fiber, a semi-crystalline polymer fiber, a cross-linked polymer fiber, a biopolymer fiber, a collagen fiber, an elastin fiber, carbon fiber, glass fiber, bioabsorbable glass fiber, silicate-containing calcium-phosphate glass fiber, ceramic fiber, polyester fiber, nylon fiber, an amorphous polymer yarn, a semi-crystalline polymer yarn, a cross-linked polymer yarn, a biopolymer yarn, carbon yarn, glass yarn, bioabsorbable glass yarn, silicate-containing calcium-phosphate glass yarn, ceramic yarn, polyester yarn, nylon yarn, or any mixture thereof.

9. The implantable device of claim 6, wherein the 1 -dimensional
reinforcement comprises an absorbable material.

10. The implantable device of claim 6, wherein the 1 -dimensional
reinforcement comprises a non-absorbable material.

11. The implantable device of claim 1, wherein the reinforcement is a
2-dimensional reinforcement.

12. The implantable device of claim 11, wherein the 2-dimensional reinforcement comprises a grid of a plurality of 1 -dimensional reinforcement elements wherein the 1 -dimensional reinforcement elements cross each other's paths.

13. The implantable device of claim 12, wherein the grid further comprises a perimeter comprising at least one 1 -dimensional reinforcement element at about a fixed distance from the device's edges.

14. The implantable device as in any of the preceding claims, wherein the suture pullout strength is from about 5 Newtons to about 75 Newtons, optionally from about 10 Newtons to about 40 Newtons.

15. The implantable device as in any of the preceding claims, wherein the break strength is from about 8.8 Newtons to about 440 Newtons, optionally from about 30 Newtons to about 100 Newtons.

16. The implantable device as in any of the preceding claims, wherein the ball burst strength is from about 1.35 Kgf to about 34 Kgf, optionally from about 3.65 Kgf to about 22.5 Kgf.

17. The implantable device as in any of the preceding claims, wherein the reticulated elastomeric matrix is configured to permit cellular ingrowth and proliferation into the reinforced reticulated elastomeric matrix.

18. The implantable device as in any of the preceding claims, wherein the implantable device is annealed before being reinforced.

19. The implantable device as in any of the preceding claims, wherein the implantable device is annealed after being reinforced.

20. The implantable device as in any of the preceding claims, wherein the implantable device is compressive molded before being reinforced.

21. The implantable device as in any of the preceding claims, wherein the implantable device is compressive molded after being reinforced.

22. A method of treating a tissue defect, the method comprising:
a) optionally compressing the implantable device as in any of the
preceding claims from a relaxed configuration to a first, compact
configuration;
b) delivering the compressed implantable device to the in vivo site of the defect via a delivery-device; and
c) optionally allowing the implantable device to expand to a second,
working configuration at the in vivo site.

23. The method of claim 22, wherein the tissue defect relates to an orthopedic application, general surgical application, cosmetic surgical application, tissue
engineering application, or any mixture thereof.

24. The method of claim 23, wherein the orthopedic application relates to a repair, reconstruction, regeneration, augmentation, gap interposition, or any mixture thereof of a tendon, ligament, cartilige, meniscus, spinal disc, or any mixture thereof.

25. The method of claim 23, wherein the general surgical application relates to an inguinal hernea, a ventral abdominal hernea, a femoral hernea, an umbilical hernea, or any mixture thereof.

26. The method as in any of claims 22-25, farther comprising securing the implantable device to the defect using a suture, anchor, barb, pin, screw, staple, plate, tack, glue, or any mixture thereof.

27. A method of treating a tissue defect, the method comprising inserting the implantable device as in any of claims 1-21 by an open surgical procedure.

28. An implantable device comprising a reticulated resiliently-compressible elastomeric matrix comprising a plurality of pores, wherein the implantable device is compressive molded after it is reticulated.

29. The implantable device of claim 28, wherein compressive molding is conducted at a temperature from about 1000C to about 1900C, optionally from about

HO0C to about 1800C.

30. The implantable device of claim 29, wherein compressive molding is conducted for a time from about 10 seconds to about 10 hours, optionally from about 30 seconds to about 5 hours.

31. The implantable device of claim 28, wherein compressive molding is conducted at a temperature of about 1600C or greater and for a time of about 30 minutes or less, optionally about 10 minutes or less.

32. The implantable device of claim 28, wherein compressive molding is conducted at a temperature of about 1300C and for a time of about 240 minutes or less, optionally about 120 minutes or less.

33. The implantable device as in any of claims 28-32, wherein the bulk density after compressive molding, as measured pursuant to the test method described in ASTM Standard D3574, is from about 0.005 g/cc to about 0.96 g/cc, optionally from about 0.048 g/cc to about 0.56 g/cc.

34. The implantable device as in any of claims 28-33, wherein the ratio of the density of the compressed reticulated elastomeric matrix to the density of the reticulated elastomeric matrix before compressive molding increases by a factor of from about 1.05 times to about 25 times, optionally from about 1.20 times to about 7.5 times.

35. The implantable device as in any of claims 28-34, wherein the tensile strength of the compressed reticulated elastomeric matrix relative to the tensile strength of the reticulated elastomeric matrix before compressive molding increases by a factor of from about 1.05 times to about 5.0 times, optionally from about 1.20 times to about 2.5 times.

36. The implantable device as in any of claims 28-35, wherein the
compressive strength of the compressed reticulated elastomeric matrix relative to the compressive strength of the reticulated elastomeric matrix before compressive molding increases by a factor of from about 1.05 times to about 4.5 times, optionally from about 1.20 times to about 3.5 times.

37. The implantable device as in any of claims 28-36, wherein the initial reticulated elastomeric matrix permeability to a fluid of at least about 450 Darcy decreases to no less than about 250 Darcy when, after compressive molding of that reticulated elastomeric matrix, the cross-sectional area is reduced by about 50%.

38. The implantable device as in any of claims 28-36, wherein the initial reticulated elastomeric matrix permeability to a fluid of at least about 200 Darcy decreases to no less than about 40 Darcy when, after compressive molding of that reticulated elastomeric matrix, the cross-sectional area is reduced by about 50%.

39. The implantable device as in any of claims 28-32, wherein the
compressive molding is conducted as a fixed mold wall compressive molding process.

40. The implantable device as in any of claims 28-32, wherein the
compressive molding is conducted as a moving mold wall compressive molding process.

41. The implantable device as in any of claims 28-32, wherein the
compressive molding is conducted in 1 -dimensional compression.

42. The implantable device of claim 41 , wherein the linear compression ratio ^ is from about 1.1 to about 9.9, optionally from about 1.5 to about 8.0.

43. The implantable device of claim 41, wherein the linear compressive strain is from about 3% to about 97%, optionally from about 15% to about 95%.

44. The implantable device as in any of claims 28-32, wherein the
compressive molding is conducted in 2-dimensional compression.

45. The implantable device of claim 44, wherein the 2-dimensional compression is radial compression.

46. The implantable device of claim 45, wherein the radial compression ratio is from about 1.2 to about 6.7, optionally from about 1.5 to about 6.0.

47. The implantable device of claim 45, wherein the cross-sectional compression ratio is from about 1.5 to about 47, optionally from about 1.5 to about 25.

48. The implantable device of claim 45, wherein the cross-sectional compressive strain is from about 25% to about 90%, optionally from about 33% to about 88%.

49. The implantable device as in any of claims 28-48, wherein the reticulated elastomeric matrix is configured to permit cellular ingrowth and proliferation into the compressive molded reticulated elastomeric matrix.

50. The implantable device as in any of claims 28-48, wherein the
implantable device is annealed before being compressive molded.

51. The implantable device as in any of claims 28-48, wherein the
implantable device is annealed after being compressive molded.

52. The implantable device as in any of claims 28-48, wherein the
implantable device is reinforced before being compressive molded.

53. The implantable device as in any of claims 28-48, wherein the
implantable device is reinforced after being compressive molded.

54. A method of treating a tissue defect, the method comprising:
a) optionally compressing the implantable device as in any of claims 28- 53 from a relaxed configuration to a first, compact configuration;
b) delivering the compressed implantable device to the in vivo site of the defect via a delivery-device; and
c) optionally allowing the implantable device to expand to a second,
working configuration at the in vivo site.

55. The method of claim 54, wherein the tissue defect relates to an orthopedic application, general surgical application, cosmetic surgical application, tissue
engineering application, or any mixture thereof.

56. The method of claim 55, wherein the orthopedic application relates to a repair, reconstruction, regeneration, augmentation, gap interposition, or any mixture thereof of a tendon, ligament, cartilige, meniscus, spinal disc, or any mixture thereof.

57. The method of claim 55, wherein the general surgical application relates to an inguinal hernea, a ventral abdominal hernea, a femoral hernea, an umbilical hernea, or any mixture thereof.

58. The method as in any of claims 54-57, further comprising securing the implantable device to the defect using a suture, anchor, barb, pin, screw, staple, plate, tack, glue, or any mixture thereof.

59. A method of treating a tissue defect, the method comprising inserting the implantable device as in any of claims 28-53 by an open surgical procedure.

60. An implantable device comprising a reticulated resiliently-compressible elastomeric matrix comprising a plurality of pores, wherein the implantable device is annealed after it is reticulated.

61. The implantable device of claim 60, wherein the annealing is carried out at a temperature in excess of about 500C, optionally, at a temperature in excess of about 1000C.

62. The implantable device as in claim 60 or 61 , wherein the annealing is carried out for at least about 2 hours, optionally, for from about 4 to about 8 hours

63. The implantable device as in any of claims 60-62, wherein the
implantable device is geometrically unconstrained while it is annealed.

64. The implantable device as in any of claims 60-62, wherein the
implantable device is geometrically constrained while it is annealed.

65. The implantable device as in any of claims 60-64, wherein the reticulated elastomeric matrix is configured to permit cellular ingrowth and proliferation into the annealed reticulated elastomeric matrix.

66. The implantable device as in any of claims 60-65, wherein the
implantable device is reinforced before being annealed.

67. The implantable device as in any of claims 60-65, wherein the
implantable device is reinforced after being annealed.

68. The implantable device as in any of claims 60-67, wherein the
implantable device is compressive molded before being annealed.

69. The implantable device as in any of claims 60-67, wherein the
implantable device is compressive molded after being annealed.

70. A method of treating a tissue defect, the method comprising:
a) optionally compressing the implantable device as in any of claims 60- 69 from a relaxed configuration to a first, compact configuration;
b) delivering the compressed implantable device to the in vivo site of the defect via a delivery-device; and
c) optionally allowing the implantable device to expand to a second,
working configuration at the in vivo site.

71. The method of claim 70, wherein the tissue defect relates to an orthopedic application, general surgical application, cosmetic surgical application, tissue engineering application, or any mixture thereof.

72. The method of claim 71, wherein the orthopedic application relates to a repair, reconstruction, regeneration, augmentation, gap interposition, or any mixture thereof of a tendon, ligament, cartilige, meniscus, spinal disc, or any mixture thereof.

73. The method of claim 71, wherein the general surgical application relates to an inguinal hernea, a ventral abdominal hernea, a femoral hernea, an umbilical hernea, or any mixture thereof.

74. The method as in any of claims 70-73, further comprising securing the implantable device to the defect using a suture, anchor, barb, pin, screw, staple, plate, tack, glue, or any mixture thereof.

75. A method of treating a tissue defect, the method comprising inserting the implantable device as in any of claims 60-69 by an open surgical procedure.

76. A polymerization process for preparing an elastomeric matrix, the process comprising admixing:
a) 100 parts by weight of a polyol component,
b) from about 10 to about 90 parts by weight of an isocyanate component, c) from about 0.5 to about 6.0 parts by weight of a blowing agent,
d) optionally, from about 0.05 to about 8.0 parts by weight of a cross- linking agent,
e) optionally, from about 0.05 to about 8.0 parts by weight of a chain
extender,
f) optionally, from about 0.05 to about 3.0 parts by weight of at least one catalyst,
g) optionally, from about 0.1 to about 8.0 parts by weight of at least one
cell opener,
h) from about 0.1 to about 8.0 parts by weight of a surfactant, and
i) optionally, up to about 15 parts by weight of a viscosity modifier;
o provide the elastomeric matrix.

77. The process of claim 76, wherein the isocyanate component has an isocyanate index and wherein the isocyanate index is from about 0.85 to about 1.2, optionally from about 0.85 to about 1.019.

78. The process as in claim 76 or 77, wherein the polyol component is liquefied prior to admixing.

79. The process as in any of claims 76-78, wherein a first admixture comprising the polyol and isocyanate components is formed by admixing the polyol component and the isocyanate component; a second admixture comprising the blowing agent and the catalyst is formed by admixing the blowing agent and the catalyst; and the first admixture and the second admixture are admixed.

80. The process as in any of claims 76-78, wherein the polyol component, the isocyanate component, the blowing agent and the catalyst are admixed in a mixing vessel.

81. The process as in any of claims 76-78, wherein a first admixture comprising the polyol component, the blowing agent and the catalyst is formed by admixing the polyol component, the blowing agent and the catalyst in a mixing vessel; and the first admixture is admixed with the isocyanate component.

82. A product of the process as in any of claims 76-81.

83. The product of claim 82, wherein the elastomeric matrix is biodurable for at least 29 days, optionally for at least 6 months.

84. A process for preparing a reticulated elastomeric matrix, the process comprising reticulating the elastomeric matrix as in any of claims 76-81 by a reticulation process to provide the reticulated elastomeric matrix.

85. The process of claim 84, wherein the permeability to a fluid of the reticulated elastomeric matrix is greater than the permeability to the fluid of an unreticulated matrix from which the reticulated elastomeric matrix was made.

86. A product of the process of claim 84.

87. The product of claim 86, wherein the reticulated elastomeric matrix product has a dynamic recovery time t-90% after 100,000 cycles at a frequency of 1 Hz in air of less than about 4,000 sec, optonally less than about 1,750 sec.

88. The product of claim 87, wherein the reticulated elastomeric matrix product has a dynamic recovery time t-90% of less than about 200 sec.

89. The product of claim 86, wherein the reticulated elastomeric matrix product has a dynamic recovery time t-90% after 100,000 cycles at a frequency of 1 Hz in water of less than about 3,000 sec, optionally less than about 1,500 sec.

90. The product of claim 89, wherein the reticulated elastomeric matrix product has a dynamic recovery time t-90% of less than about 100 sec.

91. The product of claim 86, wherein the reticulated elastomeric matrix substantially fills the biological site in which it resides.

92. The product as in any of claims 82, 83 or 86-91, wherein the reticulated elastomeric matrix is configured to permit cellular ingrowth and proliferation into the reticulated elastomeric matrix.

93. The product of claim 92, wherein the reticulated elastomeric matrix is bio-integrated into the tissue being repaired or replaced.

94. A process for preparing a reticulated elastomeric matrix, the process comprising reticulating the elastomeric matrix as in any of claims 76-81 by a combustion reticulation process to provide the reticulated elastomeric matrix.

95. The process of claim 94, wherein the permeability to a fluid of the reticulated elastomeric matrix is greater than the permeability to the fluid of an unreticulated matrix from which the reticulated elastomeric matrix was made.

96. A product of the process of claim 94.

97. A process for preparing an at least partially reticulated elastomeric matrix, the process comprising:

1) admixing:
a) 100 parts by weight of an elastomeric material,
b) optionally, from about 2 to about 70 parts by weight of a more
hydrophilic polymeric material,
c) optionally, from about 0.1 to about 20 parts by weight of a cross- linking agent, and
d) optionally, from about 1 to about 20 parts by weight of a blowing agent to form a mixture;

2) exposing the mixture to microwave irradiation at a frequency of from about 2.2 GHz to about 6.0 GHz, optionally while also heating the mixture to a temperature of from about 700C to about 225°C;

to provide the at least partially reticulated elastomeric matrix.

98. The process of claim 97, wherein the elastomeric material is is selected from polycarbonate polyurethane urea, polycarbonate polyurea urethane, polycarbonate polyurethane, polycarbonate polysiloxane polyurethane, polycarbonatepolysiloxane polyurethane urea, polysiloxane polyurethane, polysiloxane polyurethane urea, polycarbonate hydrocarbon polyurethane, polycarbonate hydrocarbon polyurethane urea, or any mixture thereof.

99. The process as in claim 97 or 98, wherein the more hydrophilic polymeric material is poly(vinyl acetate), poly(ethylene-co-vinyl acetate), or any mixture thereof.

100. The process as in any of claims 97-99, wherein the microwave irradiation is at a frequency of about 2.45 GHz or about 5.8 GHz.

101. The process as in any of claims 97- 100, wherein the temperature of the optional heating is from about 1000C to about 1800C.